MNMD$15.02
Chart
Performance
Key Stats
AI MNMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldMind Medicine (MindMed) Inc. (MNMD) shows potential in the mental health therapeutics sector with clinical stage assets, but faces significant financial challenges and market sentiment fluctuations. The company is currently in a precarious position with a need for further funding and successful clinical trial outcomes. Investors should approach with caution due to high risk and speculative nature.
Thematic
MNMD operates in the rapidly growing and increasingly important field of psychedelic medicine for brain health disorders. The thematic tailwinds are strong, driven by societal shifts in mental health treatment and ongoing research into novel therapeutic approaches. However, regulatory hurdles and the nascent stage of the industry introduce significant risk.
Fundamental
Mind Medicine (MindMed) Inc. is a pre-revenue company with no current profitability. Its financial health is characterized by significant cash burn, negative earnings, and reliance on equity financing. While it possesses substantial cash reserves, the path to profitability is long and uncertain, contingent on successful clinical development and regulatory approvals.
Technical
The technical indicators for MNMD suggest a bearish short-to-medium term outlook. The stock has experienced significant price declines over the past year, trading well below its 52-week high. While short-term momentum indicators show some mixed signals, the overall trend remains down.
| Factor | Score |
|---|---|
| Psychedelic Therapeutics Market | 85 |
| Mental Health Treatment Innovation | 70 |
| Regulatory Landscape | 40 |
| Biopharmaceutical Sector Trends | 75 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Debt Level | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 30 |
| Overall Technical Score | 35 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Performance Momentum
The stock has shown strong short-term performance, with a 1-month return of 41.4% and a 6-month return of 38.12%.
Potential Bullish Crossover
The 50-day Simple Moving Average (9.52) is above the 100-day Simple Moving Average (9.64) and the 200-day Simple Moving Average (9.73) indicating a potential shift towards a bullish trend on the daily chart.
Bearish Points (9)
Consistent Negative Earnings
The company has consistently reported negative Earnings Per Share (EPS) on a trailing twelve-month (TTM) basis (-0.75) and for the fiscal year 2024 (-4.8 PE ratio with negative income), indicating a lack of profitability.
Zero Revenue Reported
Reported revenue is zero for all periods provided (2021-2024), suggesting the company is pre-revenue and reliant on financing for operations, which carries significant risk.
Calendar
February 2020
27
Next Dividend Date
August 2025
1
Next Earnings Date
H: $-0.29
A: $-0.36
L: $-0.40
Profile
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Seasonals
Price Target
24.50 USD
The 39 analysts offering 1 year price forecasts for MNMD have a max estimate of 55.00 and a min estimate of 16.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in psychedelic-assisted therapy development for mental health disorders, notably depression.
Weight: 90
Major investor and incubator of various companies developing psychedelic and non-psychedelic mental health therapies.
Weight: 88
Clinical-stage biopharmaceutical company focused on developing a psychedelic compound (5-MeO-DMT) for treatment-resistant depression.
Weight: 85
Clinical-stage biotechnology company developing psychedelic-based therapies for mental health conditions, including depression and anxiety.